2012 ASCO Pre-Meeting Video Coverage

Published: Thursday, May 31, 2012

Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses:
Crizotinib for Pediatric Patients With ALCL
Research From the 2012 ASCO Meeting
Dr. Markman on PCP Awareness of Long-Term Side Effects
Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses a large survey that will be presented at the 2012 ASCO Annual Conference, focusing on primary care provider (PCPs) awareness of long-term side effects (LEs) in cancer survivors.
View more >>>
Dr. Chapman on BRAF/MEK Combination for Melanoma
Paul B. Chapman, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses combination therapy with dabrafenib and trametinib, two investigational agents for patients with advanced melanoma that have a V600 BRAF mutation.
View more >>>
Leonard G. Gomella, MD, Bernard W. Godwin Jr. professor of prostate cancer and chairman of the Department of Urology, director of Clinical Affairs, Jefferson Kimmel Cancer Center, discusses:
Neoadjuvant Hormonal Therapy Plus Zytiga
The Unique Attributes of Neoadjuvant Zytiga
Dr. Kazmi Discusses Olanzapine for Breakthrough CINV
Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting.
View more >>>
Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses:
The Dabrafenib/Trametinib Combination
BRAF/MEK Combination Side Effects
 

<<< View more from the 2012 ASCO Conference

Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses:
Crizotinib for Pediatric Patients With ALCL
Research From the 2012 ASCO Meeting
Dr. Markman on PCP Awareness of Long-Term Side Effects
Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses a large survey that will be presented at the 2012 ASCO Annual Conference, focusing on primary care provider (PCPs) awareness of long-term side effects (LEs) in cancer survivors.
View more >>>
Dr. Chapman on BRAF/MEK Combination for Melanoma
Paul B. Chapman, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses combination therapy with dabrafenib and trametinib, two investigational agents for patients with advanced melanoma that have a V600 BRAF mutation.
View more >>>
Leonard G. Gomella, MD, Bernard W. Godwin Jr. professor of prostate cancer and chairman of the Department of Urology, director of Clinical Affairs, Jefferson Kimmel Cancer Center, discusses:
Neoadjuvant Hormonal Therapy Plus Zytiga
The Unique Attributes of Neoadjuvant Zytiga
Dr. Kazmi Discusses Olanzapine for Breakthrough CINV
Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting.
View more >>>
Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses:
The Dabrafenib/Trametinib Combination
BRAF/MEK Combination Side Effects
 

<<< View more from the 2012 ASCO Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x